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Abstract
Viruses cleave cellular proteins to remodel the host proteome. The study of these cleavages
has revealed mechanisms of immune evasion, resource exploitation, and pathogenesis.
However, the full extent of virus-induced proteolysis in infected cells is unknown, mainly
because until recently the technology for a global view of proteolysis within cells was lacking.
Here, we report the first comprehensive catalog of proteins cleaved upon enterovirus infec-
tion and identify the sites within proteins where the cleavages occur. We employed multiple
strategies to confirm protein cleavages and assigned them to one of the two enteroviral pro-
teases. Detailed characterization of one substrate, LSM14A, a p body protein with a role in
antiviral immunity, showed that cleavage of this protein disrupts its antiviral function. This
study yields a new depth of information about the host interface with a group of viruses that
are both important biological tools and significant agents of disease.
Author summary
Enteroviruses are associated with a variety of human diseases, including gastroenteritis,
the common cold, hand-foot-and-mouth disease, acute hemorrhagic conjunctivitis, and
skin rash. In some cases, the infection can lead to myocarditis, encephalitis, progressive
muscle weakness, and paralysis. Exactly how enteroviruses invade human tissues, defeat
the host immune system, and alter normal cell biology is unknown. Understanding these
cellular and molecular mechanisms will blaze the trail for the development of novel vac-
cine and therapeutic strategies. Here, we have applied a global N-terminomics approach
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to investigate how various enteroviruses recruit their proteases to remodel an infected
cell, disarm host immunity, and create a favorable environment for their replication. This
effort identified several new protease substrates, which we then confirmed by other exper-
imental approaches. To our knowledge, this is the first systematic analysis of host proteins
targeted for cleavage during enterovirus infection. The data generated in this study will
serve as a valuable resource for the research community in the quest to uncover the molec-
ular details of enterovirus cell biology and disease pathogenesis.
Introduction
Viruses hijack or subvert host cell machinery to create a favorable environment for their repli-
cation. One way they do this is by cleaving host proteins. A number of viruses encode one or
more proteases that cleave cellular proteins during infection in a spatially and temporally regu-
lated manner, while other viruses recruit host proteases to promote their replication. Over the
years, numerous proteins involved in diverse cellular processes including gene expression,
autophagy, apoptosis, vesicular transport, and antiviral immunity have been identified as pro-
teolytic targets upon virus infection [1–4]. The study of these cleavages has helped unravel the
complex interplay between viruses and their hosts, as well as advanced our understanding of
cell biology. However, technical limitations have meant that targets of viral proteases are gen-
erally identified one at a time, so the full extent of proteolysis induced upon infection remains
unknown. In this study, we report the first comprehensive view of host proteins cleaved upon
enterovirus infection.
Enteroviruses are one of the leading causes of human disease worldwide. Classified in the
Picornaviridae family, the enterovirus genus comprises over 300 genotypes grouped into 10
enterovirus (EV) species (EV-A to EV-J) and three rhinovirus (RV) species (RV-A to RV-C)
(reviewed in [5]). The enteroviruses cause a range of diseases, including the common cold
(human rhinoviruses [HRV]), hand-foot-and-mouth disease (Coxsackievirus, enterovirus A71
[EV71], and others), acute hemorrhagic conjunctivitis (enterovirus D70 [EV70]), poliomyelitis
(poliovirus), and recent outbreaks of acute flaccid paralysis (possibly associated with enterovi-
rus D68 and others). In some cases, infection can lead to severe neurological disease, myocar-
ditis, and encephalitis, and these viruses have been implicated in epidemics and deaths
worldwide. Enteroviruses, such as poliovirus, have also been used for decades as tools to probe
virus-host interactions.
Enteroviruses possess a positive-stranded RNA genome of around 7,500 nucleotides that is
composed of a long open reading frame (ORF) flanked by untranslated regions (UTR). The 5’
UTR contains an internal ribosomal entry site (IRES) that drives cap-independent translation
of the ORF to generate a large precursor polyprotein [6, 7]. Embedded in this polyprotein are
two proteases, 2A (2Apro) and 3C (3Cpro), that cleave the polyprotein co- and post-translation-
ally to liberate 11 mature proteins [8, 9]. In the context of viral polyprotein processing, 2Apro is
only responsible for its own cleavage from the upstream structural protein [10], and all but
one of the remaining cleavages are catalyzed by 3Cpro [8]. The final cleavage occurs by an auto-
catalytic mechanism [11].
Enteroviral proteases cleave host proteins as well. This was first described during the 1980s
when poliovirus 2Apro was shown to cleave eIF4G, an essential translation initiation factor
required for cap-dependent translation of host mRNAs [12]. As a result of eIF4G cleavage,
host translation shuts off, while cap-independent viral RNA translation remains intact. It is
believed that by blocking host translation, poliovirus and other enteroviruses suppress the
expression of antiviral genes and thereby create a favorable environment for virus replication.
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Since the discovery of eIF4G cleavage, several more cellular proteins have been identified as
enteroviral protease substrates. However, most of these proteins were discovered by either candi-
date approaches, two-dimensional (2D) gel electrophoresis, or in silico predictions [13, 14]. These
methods, while useful, are limited in their ability to provide a global view of proteolysis in a cell.
With recent advances in proteomics, several methods are now available that allow unbiased
labeling of newly generated protein N-termini (neo N-termini), such as those resulting from
proteolytic cleavage [15–17]. These methods leverage the fact that ~85% of the nascent protein
N-termini in mammalian cells are post-translationally modified, mainly by acetylation, and are
therefore unavailable for labeling [18]. One labeling method utilizes a bioengineered protein ligase,
subtiligase, to append a biotinylated peptide to the neo N-termini produced inside the cells [16].
The biotinylated proteins are then captured on streptavidin beads, subjected to on-bead trypsiniza-
tion, released from the beads through tobacco etch virus (TEV) protease cleavage, and identified
by highly sensitive mass spectrometry (LC-MS/MS). The biotinylated peptide is designed such
that after being removed by the TEV protease, it leaves a non-natural amino acid mass tag (amino-
butyric acid, or Abu) attached to the neo N-terminal end, enabling high-confidence identification
of the labeled peptides over nonspecifically bound background [19]. This method has been exten-
sively used to study caspase-mediated proteolysis during apoptosis [16, 19, 20]. Another N-termi-
nomics approach was recently used to investigate cellular proteins cleaved by enteroviral 3Cpro in
cell lysates [21], but this technique has not been attempted in the context of infection.
In this report, we adapted the subtiligase labeling approach for global identification of pro-
teins cleaved upon virus infection. By applying this method to five viruses from diverse entero-
viral species, we identified numerous known and novel cellular targets that we then validated
with orthogonal approaches. Among the newly identified cleavage substrates was LSM14A, a p
body-resident protein previously implicated in defense against some RNA and DNA viruses
[22]. We show that the enteroviral 2Apro-mediated cleavage of this protein prevents it from
boosting antiviral defenses.
Results
Hundreds of host protein cleavage events detected after Coxsackievirus B3
infection
To map the landscape of enterovirus-induced proteolysis, we adapted a subtiligase method for
labeling newly-cleaved N-termini in infected cells [20]. We chose to use Coxsackievirus B3
(CVB3) for initial analysis, as its known proteolytic targets could be used for validation. As a
first step, we optimized the protocol to reduce the number of cells required and to allow simul-
taneous handling of multiple samples, which were prerequisites for time course analysis of
virus infection with multiple replicates. Sonication of cells in buffer containing 1% SDS, fol-
lowed by depleting the lysates of detergent prior to the labeling reaction, ensured optimal lysis
(as measured by histone H3 solubilization, S1A Fig) and robust subtiligase-mediated biotinyla-
tion (S1B Fig). Optimization of post-lysis steps showed that 3 mg cellular protein per labeling
reaction was sufficient for identification of the known enteroviral targets, as opposed to 30 mg
per reaction reported previously for detection of caspase-mediated cleavages [20]. Similarly,
we optimized the wash conditions to achieve greater signal over background. Next, we deter-
mined the timing of HeLa cell infection using CVB3 encoding an enhanced green fluorescent
protein (eGFP) reporter gene (eGFP/CVB3). GFP-positive cells were first detected at around 3
hours post-infection (h.p.i.), and the infection reached its peak within the next hour (S2A Fig).
The cytopathic effects (CPE) of infection were obvious by 6 h.p.i.
The optimized subtiligase method was used to label free N-termini in uninfected and
CVB3-infected HeLa cells at various times post-infection (Fig 1A). Newly-cleaved peptides
PLOS PATHOGENS Enterovirus-induced proteolysis
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Fig 1. Analysis of protein cleavages in HeLa cells upon eGFP/CVB3 infection. (A) Subtiligase labeling workflow. HeLa cells were either infected with a virus
or left uninfected, lysed in SDS buffer, and the lysates containing 3 mg total protein were subjected to subtiligase enrichment of protein N-termini. LC-MS/MS
identification and bioinformatics analysis of the enriched N-termini yielded a list of virus-induced protein cleavages. (B) HeLa cells infected with eGFP/CVB3
were harvested in triplicate at the indicated times post-infection followed by subtiligase labeling. Each row indicates a unique Abu-labeled peptide, and the red
and black colors are used to show the presence and absence of the peptide, respectively. The peptides are presented in no particular order. (C) Frequencies of
P1 and P1´ amino acids from unique N-termini identified at the indicated times post-infection. The N-termini present in at least two of the three replicates
were included in this analysis. (D) Frequencies of protein cleavages derived from the indicated P1 and P1´ amino acid pairs at various times post-infection.
Only the cleavages seen in at least two of the three replicates were counted.
https://doi.org/10.1371/journal.ppat.1008927.g001
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in each lysate were analyzed by LC-MS/MS, with triplicate samples for each time point.
From this experiment, we identified many free N-termini in both infected and uninfected
cells. Interestingly, the magnitude of labeling increased as the infection progressed, suggest-
ing an increase in the number of neo N-termini (Fig 1B and S2B Fig). Indeed, considering
only peptides that appeared in at least two of the three replicates for LC-MS/MS, the number
of label-accessible peptides in the infected cells increased from 868 (at 2 h.p.i.) to 995 (at
4 h.p.i) to 1458 (at 6 h.p.i) (Table 1). Out of the 995 peptides identified at 4 h.p.i., 455 were
found only in the infected cells, and the number of infection-specific peptides increased to
978 at 6 h.p.i.
Viral and cellular proteases exhibit cleavage site preferences, allowing the terminal residues
of the cleavage products to provide clues about the identity of the protease. Enteroviral 2Apro
and 3Cpro are chymotrypsin-like proteases with a cysteine nucleophile and cleave the viral
polyprotein at consensus motifs mainly defined by the P1 and P1´ residues. 3Cpro exhibits
strict site specificity for glutamine (Q) at the P1 position and glycine (G) > alanine (A) > ser-
ine (S) at the P1´ position [8, 13]. Interestingly, 21% of N-termini identified in CVB3-infected
cells at 6 h.p.i. were derived from P1 glutamine cleavage, in contrast to 4% in uninfected cells
(Fig 1C: top panel and Table 1). In addition, we observed 10- and 30-fold more Q-G cleavages
at 4 and 6 h.p.i., respectively, compared to uninfected cells (Fig 1D: left panel, and Table 1).
The number of Q-A and Q-S cleavages also increased upon infection (Table 1). In contrast to
3Cpro, 2Apro can tolerate multiple P1 residues, although it prefers threonine (T), tyrosine (Y),
and phenylalanine (F). It however has a strict requirement for G at the P1´ position. In line
with this, P1´ glycine cleavages increased by 3-fold upon virus infection (Fig 1C: bottom panel,
and Table 1). As the infection progressed, more cleavages were observed at the 2Apro motifs
(Fig 1D: middle and right panels, and S3 Fig). The greatest increase was seen for T-G cleavages,
which rose from 0.2% at 2 h.p.i. to 4.5% at 6 h.p.i. (Fig 1D: right panel). Although some of
these cleavages might be catalyzed by host proteases, the fact that they were seen at generally
much lower levels in the uninfected cells supports the hypothesis that they were mediated by
the viral proteases.
Table 1. Summary of CVB3 induced proteolysis in HeLa cells. The total numbers of peptides and the corresponding proteins in the mock and virus-infected cells are
tabulated. For several proteins, multiple peptides were identified, suggesting that those proteins were cleaved at more than one site. Also, the numbers of cleavages at the
indicated motifs are shown.
Cleavages (P1|P1´ residues) Mock Peptides (proteins) 2h Peptides (proteins) 4h Peptides (proteins) 6h Peptides (proteins)
Total 876 (702) 868 (698) 995 (776) 1458 (1087)
Q|X�� 32 (31) 27 (27) 65 (61) 258 (239)
X|G 123 (107) 131 (116) 238 (203) 647 (518)
D|X 36 (32) 34 (28) 41 (36) 134 (124)
Q|G 3 (3) 3 (3) 29 (26) 148 (137)
Q|A 6 (6) 6 (6) 8 (8) 36 (36)
Q|S 14 (14) 11 (11) 17 (17) 58 (58)
T|G 2 (2) 3 (3) 26 (26) 66 (62)
Y|G 11 (10) 10 (10) 20 (18) 41 (39)
F|G 6 (6) 8 (8) 15 (15) 24 (23)
V|G 2 (2) 3 (3) 3 (3) 9 (9)
A|G 11 (11) 10 (10) 10 (10) 30 (30)
�� any amino acid
https://doi.org/10.1371/journal.ppat.1008927.t001
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At later stages of infection, enteroviruses are known to induce apoptosis. The effector prote-
ases in the apoptotic pathway, caspases, cleave their targets between aspartate (D) and small
amino acids (G> S> A) [23, 24]. At 6 h.p.i., when the cells exhibited substantial CPE, 134 of
the neo N-termini were derived from P1 aspartate cleavage, in contrast to 41 at 4 h.p.i (Table 1).
This suggests that caspases are also impacting the proteolytic landscape of CVB3-infected cells.
Overall, these results indicate that hundreds of cleavages take place in CVB3-infected cells,
and that many of the resulting peptides show the signatures of 2Apro, 3Cpro, and caspase cleav-
age. Furthermore, these results suggest that the modified subtiligase labeling conditions are
well suited for identifying protein cleavages in virus-infected cells.
Multiple novel targets of CVB3 proteases identified and validated
As an initial validation of the subtiligase labeling approach, we inspected the dataset of all
newly-cleaved proteins for the presence of known CVB3 targets. CVB3 has been reported to
cleave a number of host proteins, including dystrophin, eIF4G, HNRPD, HNRPM, MAVS,
NUP98, PABP, RIP3, and TRIF [1]. Peptides from the majority of these proteins were present
in our dataset, with the exceptions of RIP3, which is not expressed in HeLa cells [25], and dys-
trophin. Most importantly, the peptides for eIF4G, HNRPD, HNRPM, MAVS, and PABP cor-
responded to the known cleavage sites in these proteins, although additional peptides were
also detected. These findings supported the validity of our labeling approach.
Next, we surveyed our dataset for the presence of novel cleavage targets. To ensure high-
confidence identification of targets, we included only those proteins that were detected in at
least two of the three infected, but none of the uninfected, replicates. Similarly, to exclude non-
specific cleavages, we included proteins that were cleaved early during infection before the
cells reached cytotoxicity. This yielded a list of 173 proteins (S1 File), of which around 81 were
cleaved at motifs known to be targeted by CVB3 proteases. These proteins are involved in
numerous cellular pathways, including transcription, RNA editing, splicing, transport, and
turnover, cytoskeleton maintenance, cell division, DNA repair, endocytosis and secretion, and
innate immunity. We chose 20 of these 81 proteins, along with 14 late-stage targets (ARFP1,
CAPR1, CHERP, DBNL, F120A, HTSF1, MAPK3, MATR3, NUFP2, PANX1, RBP56,
SHRM1, SP130, and STAT3) and six known targets (EIF4G, HNRPD, HNRPM, MAVS,
NUP98, and USO1) identified in our dataset, for validation studies (Fig 2B).
To validate cleavage of the candidate target proteins in the presence of virus, we infected
HeLa cells with eGFP/CVB3 and monitored the proteins over time by western blot (Fig 2A
and S4 Fig). Remarkably, all proteins tested were cleaved, with around 75% of them yielding
the banding pattern consistent with the cleavage site(s) identified by degradomics. For some
proteins, the full-length molecules decreased in abundance without yielding a detectable cleav-
age product. This is likely due to alteration of the epitope recognized by the antibodies used or
progressive degradation of the cleavage products. To test if the epitope alteration was responsi-
ble for the lack of detectable cleavage product, we generated doubly-tagged versions of some
proteins fused at their N-terminal end with a V5 tag and at their C-terminal end with an HA
tag. Should the protein be cleaved, western blot with anti-V5 and anti-HA antibodies would
identify N-terminal and C-terminal cleavage products, respectively. Of the five proteins tested,
four had detectable cleavage products (S5 Fig).
Importantly, the western blot results confirmed the timing of proteolytic cleavage as
observed in the proteomics dataset. EIF4G and NUP98 were cleaved within 2h of infection,
while other proteins were mostly cleaved at 4 h.p.i. This was the time point at which GFP
became detectable, suggesting an overlap between virus replication and protein cleavage (Fig
2B). For 12 proteins, cleavage was detected only at 5 h.p.i. Among these, seven were consistent
PLOS PATHOGENS Enterovirus-induced proteolysis
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with the proteomics results, while the remaining five were found to be cleaved earlier in the
proteomics experiment, suggesting that subtiligase enrichment can be more sensitive than
western blot. Overall, these results suggest that N-terminal subtiligase labeling is a robust
method to identify infection-associated cleavage targets and that labeling correlates well with
the timing of cleavage events.
Purified recombinant CVB3 proteases cleave identified target proteins in
vitro
To test if CVB3 proteases were responsible for the cleavages identified, we performed an in
vitro cleavage assay. For this, we incubated HeLa cell lysates with purified recombinant CVB3
2Apro and 3Cpro proteases, or their catalytically inactive versions, and monitored the cleavage
of 38 of the identified substrates by western blot (Fig 3 and S6 Fig). It should be noted that
although this method has previously been used to test protein cleavage [21, 26], the results can
be heavily influenced by the quality of the protein preparations, buffer composition, the prote-
ase-to-protein ratio, and the reaction conditions. Therefore, we first optimized all of these
parameters. Preparation of cell lysates in a mild detergent (0.1% Triton-X) and incubation of
lysates with viral proteases at a protease to protein ratio of 1:200 for 2Apro and 1:4 for 3Cpro
yielded optimal results.
Fig 2. Validation of protein cleavages identified by subtiligase labeling. (A) HeLa cells were infected with eGFP/CVB3 and lysed at 0, 2, 3, 4, 5, and 6 h.p.i.
followed by western blot analysis of the indicated proteins. An equal amount of total protein, as quantified by the BCA assay, was loaded for each time point. GFP
expression was used to monitor the progression of infection (bottom panel). The black solid arrows indicate the full-length protein, while the cleavage products are
shown with red dotted arrows. (B) The post-infection time point when the cleavage first became detectable is shown (the western blot images are shown in S4 Fig).
Some proteins (CAPR1, HTSF1, MAPK3, MAVS, SP130, STAT3, and USO1) that were found to be cleaved only at 6 h.p.i by proteomic analysis were included as
controls. The proteins with asterisks were found to be cleaved at 4 h.p.i. by proteomics analysis but only at 6 h.p.i. by western blot. The position and identity of P1
residues identified at either 4 or 6 h.p.i. and the biological functions of the cleaved proteins are also shown.
https://doi.org/10.1371/journal.ppat.1008927.g002
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The in vitro assay showed that the presence of CVB3 proteases resulted in cleavage of all 38
proteins monitored. The results of the in vitro assay largely agreed with the protease suscepti-
bility predicted from the cleavage sites. In general, sites with a P1 glutamine were cleaved by
3Cpro, while the rest were catalyzed by 2Apro. While most of the proteins underwent cleavage
only once, some were targeted multiple times either by the same or different proteases. For
example, HNRPM appeared to be repeatedly targeted by 2Apro (S6 Fig, 4th lane, middle panel).
In contrast, MATR3, which yielded two C-terminal cleavage products in the infected cells, was
independently targeted by both 2Apro and 3Cpro at two different sites (Fig 3). Consistent with
the infection results, some proteins (ARFP1, F120A, HTF4, NHEJ1, NUFP2, PANX1, and
SP130) decreased in abundance but did not produce detectable cleavage products. In all, these
results suggest that the viral proteases were responsible for most of the cleavages identified at
early time points in CVB3-infected cells.
Identification of proteins targeted for cleavage by multiple enteroviruses
We were interested in comparing the proteolytic landscape of CVB3 infection to that of other
enteroviruses, and to determine if common targets of proteolysis exist. To do this, we used a
panel of enteroviruses associated with various human disease states: human rhinovirus A16
(HRV), poliovirus 1 (PV), enterovirus D70 (EV70), and enterovirus A71 (EV71). First, we
tested the growth kinetics of these viruses in HeLa cells by monitoring the accumulation of
Fig 3. In vitro cleavage assay of the identified proteins. (A) HeLa cell lysates (200 μg protein) were incubated with
CVB3 2Apro or its catalytically inactive mutant C110A (1 μg), or CVB3 3Cpro or its catalytically inactive mutant C147A
(100 μg) at 37˚C for 3h and analyzed by western blot. Lysates from the uninfected and eGFP/CVB3-infected HeLa cells
were included as positive controls. The full-length protein is indicated with black solid arrows, while the cleavage
products are indicated with red dotted arrows. (B) The proteins are grouped into three categories based on if the
cleavage was mediated by 2Apro, 3Cpro or both (the western blot images are shown in S6 Fig).
https://doi.org/10.1371/journal.ppat.1008927.g003
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viral proteins (S7 Fig). PV exhibited the same characteristics as CVB3, with most of the cells
expressing the viral antigens at 4 h.p.i. and exhibiting cytotoxicity at 6 h.p.i. EV70 and EV71
had slower growth kinetics, reaching peak infection at 6 h.p.i. HRV was the slowest of all with
the highest number of infected cells seen at 9 h.p.i. Based on this, we selected 3, 4, and 6 h.p.i.
time points for PV, 4, 6, and 8 h.p.i. for EV70 and EV71, and 6, 9, and 12 h.p.i. for HRV. For
each virus, uninfected HeLa cells served as a control.
Proteomic analysis of subtiligase-labeled neo N-termini from cells infected with these
viruses revealed 218 (PV), 278 (HRV), 274 (EV70), and 206 (EV71) candidate host targets of
cleavage. This was comparable to the 211 host proteins identified for CVB3 (Fig 4A and S2
File). As expected from the structural and functional similarities of enteroviral proteases [1],
many of the identified target proteins overlapped between one or more viruses; 46 proteins
were detected as cleaved by all viruses tested. Some cleavages appeared specific to a single virus
or a subset of viruses; however, unless confirmed by orthogonal approaches, it is difficult to
Fig 4. Analysis of proteins broadly targeted by enteroviruses. (A) Venn diagram showing the numbers of cleaved proteins
common or unique to different viruses. (B) STRING interaction network of proteins targeted by at least two of the five
enteroviruses as rendered in Cytoscape (disconnected nodes are not shown). Coloring indicates groups of five or more
proteins identified as highly interconnected by the MCODE clustering algorithm. Most significantly enriched biological
processes are summarized below the network. Cleaved proteins validated by western blot are shown in diamond shaped
nodes. (C) Top 15 significantly enriched biological processes targeted by at least two of the five viruses.
https://doi.org/10.1371/journal.ppat.1008927.g004
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conclude with confidence that a particular cleavage is virus-specific. This is because subtiligase
labeling, like other proteomics-based approaches, may not identify all protein cleavages across
samples, and peptides could also be excluded by the strict data analysis pipeline. Protein clus-
tering and gene ontology (GO) enrichment analysis on proteins identified with high confi-
dence for at least two of the five viruses (Fig 4B and 4C) showed enrichment of proteins from
gene expression pathways, such as RNA splicing, mRNA export from the nucleus, translation
initiation, and RNA metabolism. This aligned with previous observations that enteroviruses
strongly inhibit gene expression (reviewed in [27]).
To identify common substrates of enterovirus proteases, and to narrow the candidates to a
manageable number of samples, we focused on the 40 proteins that we had previously vali-
dated for CVB3. Most of these proteins were detected as cleaved in all proteomics datasets
obtained, indicating that they were targeted by all viruses tested (S8 Fig). Some proteins
(I2BP2, DSRAD, and MAVS) appeared to be cleaved by a subset of viruses, with two (DDX6
and DHX9) detected in only CVB3- and EV71-infected cells. Importantly, for most proteins,
the same peptides were detected in the datasets of all viruses tested, indicating specific cleavage
instead of non-specific degradation.
To validate the proteomics results for the panel of enteroviruses, we infected HeLa cells
with each virus and tested cleavage of the 40 candidate targets by western blot at two different
times post-infection (Fig 5 and S9 Fig). To determine whether diverse viral proteases also
cleaved these substrates, we infected cells with two non-enteroviruses: Venezuelan equine
encephalitis virus (VEEV), a positive-strand RNA virus from the Togaviridae family, and vesic-
ular stomatitis virus (VSV), a negative-strand RNA virus from the Rhabdoviridae family. The
western blot results largely confirmed the cleavage patterns revealed by the subtiligase labeling
experiments. For example, consistent with the proteomics results, DDX6 and DHX9 were
exclusively cleaved by CVB3 and EV71, although a faint band indicating cleavage at a different
site was noted for DHX9 in PV-infected cells (Fig 5). In contrast to the proteomic results, west-
ern blot showed that MAVS was targeted by all viruses tested and, interestingly, seemed to be
cleaved at different sites by different enteroviruses. This was also true for F120A, where more
prominent cleavage bands were seen for HRV compared to CVB3 and PV, despite the fact that
all of these viruses caused a similar decrease in the full-length protein (S9 Fig). This may be
due to differential stability of the cleavage products generated by different viruses. For the
most part, VEEV and VSV infection did not lead to cleavage of the cellular proteins tested,
with the exception being incomplete cleavage of CT2NL by VSV and some degradation of
MAVS by both viruses. Overall, these results again indicate that subtiligase labeling is a power-
ful technique to identify protein cleavage events associated with virus infection, and that the
cleavages identified are largely specific to enterovirus infection as opposed to pan-viral.
Since our analysis had so far been limited to HeLa cells, we next investigated proteolysis of
the identified targets by eGFP/CVB3 and PV in various cell types (S10 Fig). The panel of cell
lines included Caco-2, an intestinal epithelial line representing the primary portal of CVB3
and PV entry into human body, RD, a skeletal muscle line representing one of the major sites
of PV replication in vivo, and SK-N-SH, a neuronal line likely relevant for the neurotropic
potential of enteroviruses. We also infected embryonic stem cell-derived neural progenitor
cells (NPC) to test protein cleavage in a more physiologically relevant setting. Since CVB3 did
not infect RD cells and only minimally infected SK-N-SH cells, we excluded these cells from
CVB3 analysis. Notably, the selected proteins were found to be cleaved in all cell types tested,
and the banding patterns mostly resembled those seen in HeLa cells. Taken together, the
results so far suggest that enteroviruses mostly cleave an overlapping set of proteins, and that
these cleavages are consistent across a variety of cell types.
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LSM14A is a novel innate immune response target cleaved and inactivated
by enterovirus proteases
LSM14A was identified in our analysis as a protein broadly targeted by enteroviruses in a vari-
ety of cell types (Fig 5 and S10 Fig) and mature neurons (S11 Fig). This protein mainly resides
in p bodies, cytoplasmic ribonucleoprotein granules involved in mRNA turnover, and has
been previously implicated in antiviral immunity against some DNA and RNA viruses [22].
Our studies indicated that LSM14A cleavage is mediated by 2Apro (Fig 3) at a recognition site
with a P1´ G. To validate this target site, we changed the P1´ glycine (G147) to either alanine
(A) or glutamate (E) and tested if these mutants were cleaved upon virus infection (Fig 6A).
Intriguingly, the G147A and G147E proteins were still cleaved, albeit less efficiently. Also, the
size of the cleaved product was larger than with the wild-type protein, suggesting that the
mutant proteins were cleaved at an alternate, upstream site (Fig 6B).
Next, we performed functional assays to test if LSM14A cleavage renders the protein non-
functional. LSM14A has been reported to enhance innate immunity upon Sendai virus (SeV)
infection [22]. To confirm this, we expressed LSM14A in 293T cells containing reporter plas-
mids ISRE-FLuc and RL-RLuc and infected these cells with SeV. SeV infection should activate
IRF3/7, which binds to the Interferon-Stimulated Response Element (ISRE) in the ISRE-FLuc
Fig 5. Validation of proteins targeted by multiple enteroviruses. (A) HeLa cells infected with CVB3 (eGFP-Coxsackievirus B3), PV (poliovirus
type 1), HRV (human rhinovirus A16), EV70 (enterovirus D-70), EV71 (enterovirus A-71), VEEV (Venezuelan equine encephalitis virus) or VSV
(vesicular stomatitis virus) were lysed at the indicated times, and equal amounts of total protein were subjected to western blot with the indicated
antibodies. The black solid and red dotted arrows indicate the full-length protein and the cleavage products, respectively. (B) The western blot
results are summarized to show proteins commonly targeted by all five enteroviruses and those unique to a subset of viruses (the western blot
images are shown in S9 Fig).
https://doi.org/10.1371/journal.ppat.1008927.g005
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reporter to promote Firefly luciferase (FLuc) expression. As a comparator, Renilla luciferase
(Rluc) is expressed from RL-RLuc under the control of the CMV promoter, and its levels
should remain stable. As expected, expression of LSM14A enhanced SeV-mediated ISRE acti-
vation in a dose-dependent manner, confirming the role of this protein in innate immunity
(Fig 7A: Right panel). Interestingly, however, LSM14A exhibited no activity in the absence of
SeV (Fig 7A: Left panel). This was unlike another innate immune signaling factor, MAVS (S12
Fig), and raises the possibility that LSM14A has a role in RNA sensing.
We took two approaches to test how the enterovirus-mediated cleavage affects LSM14A
activity. First, we separately expressed the cleavage products in 293T cells and tested their abil-
ity to enhance SeV-induced ISRE activation. As might be expected, the individual LSM14A
cleavage products did not enhance the ISRE activity (Fig 7B). In a second approach, we engi-
neered a TEV protease (TEVpro) recognition site into LSM14A at the location of the enterovi-
rus 2Apro cleavage. We then tested ISRE activation in the presence or absence of TEVpro.
Importantly, the modified LSM14A showed comparable ISRE-FLuc activation as its wild-type
counterpart in 293T cells, indicating that the insertion of the TEVpro cleavage site did not dis-
rupt its function (S13A Fig). In the presence of TEVpro, however, the modified LSM14A
underwent cleavage (S13B Fig) and could no longer enhance SeV-mediated immune activa-
tion (Fig 7C). These results clearly indicated that the N- and C-terminal cleavage products of
LSM14A do not cause ISRE activation upon SeV infection.
Exactly how LSM14A contributes to antiviral immunity is unknown. To gain insights into
LSM14A mechanism, we examined its ISRE-activating potential in 293T cells lacking various
components of antiviral immune signaling. Absence of MAVS abrogated the ability of
LSM14A to enhance SeV-mediated immune signaling, suggesting that LSM14A functions
upstream of MAVS (Fig 7D). Depletion of RIG-I (a known SeV sensor) also blocked LSM14A
activity, indicating that LSM14A might function as a RIG-I co-factor or alternatively partici-
pate in signaling only once the pathway is activated. Finally, LSM14A activity was unaffected
when STAT1 was knocked out (Fig 7D), implying that the protein does not work through
Fig 6. Validation of LSM14A cleavage. (A) Schematics of the LSM14A constructs generated for validation of the cleavage site. The cleavage site and the flanking eight
amino acids are shown in the cartoon. The P1 glycine that was mutated is shown in red. (B) HeLa cells transduced to stably express the LSM14A constructs were
infected with eGFP/CVB3 or PV, and the LSM14A cleavage was analyzed by western blot. The blots were probed with mouse anti-V5 and rabbit anti-HA antibodies
followed by detection with IRDye 680RD goat anti-mouse IgG (red channel) and IRDye 800CW goat anti-rabbit IgG (green channel). FL, full-length protein; CT, C-
terminal cleavage product; NT, N-terminal cleavage product; M, mock; CV; eGFP/CVB3; PV, poliovirus; UBC, Ubiquitin C.
https://doi.org/10.1371/journal.ppat.1008927.g006
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Fig 7. Functional assays of LSM14A. (A) LSM14A activated ISRE in a dose-dependent manner. The 293T cells (30,000 cells per well in 48-well plates) expressing the
ISRE-FLuc and RL-RLuc reporters were transfected with the indicated amounts of GFP (vector) or LSM14A plasmids. The next day, the cells were left uninfected (left
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interferon signaling. To further investigate whether LSM14A functions upstream of MAVS, we
generated LSM14A knockout cells and examined the ability of MAVS to induce immune signal-
ing in this setting. MAVS activity remained largely unchanged upon LSM14A depletion, support-
ing the hypothesis that MAVS acts downstream of LSM14A (Fig 7E). To examine the possibility
that LSM14A is an essential RIG-I co-factor, we tested SeV-induced immune signaling in
LSM14A knockout cells. Interestingly, LSM14A depletion did not suppress SeV-mediated ISRE
activation (Fig 7F), precluding the role of LSM14A as a critical RIG-I cofactor. Taken together, it
appears that LSM14A promotes but is not essential for RIG-I signaling in 293T cells. Cleavage of
this protein, along with cleavage of MAVS, may help enteroviruses evade host defenses.
Discussion
Despite mounting evidence that enteroviruses employ proteolysis to modulate or usurp host
machinery, the true extent of proteolysis in a virus-infected cell remains unknown. Here, we
took a relatively unbiased N-terminomics approach to obtain the first comprehensive catalog
of cellular proteins that undergo cleavage upon enterovirus infection. This led to the identifica-
tion of a number of known and novel substrates from diverse cellular pathways. As expected
from the structural and functional similarities of enteroviral proteases [1], many of the identi-
fied proteins were targeted by all viruses tested. However, some interesting differences in the
cleavage patterns emerged. For example, as demonstrated by both N-terminal labeling and
western blot, DDX6 and DSRAD were efficiently cleaved only in the CVB3-infected cells. Sim-
ilarly, NUP98 and DHX9 appeared to be targeted with different efficiencies by different
viruses, while MAVS and F120A were cleaved by all viruses but at varying sites. Importantly,
these patterns, although originally identified in HeLa cells, were seen in all cell types tested,
indicating that they reflect the true virus-host biology instead of cell culture artifacts. To inves-
tigate the relevance of the cleaved proteins, we followed up on one candidate, LSM14A, and
showed that the truncated forms of this protein generated by enterovirus 2Apro-mediated
cleavage do not cause ISRE activation in response to SeV infection.
LSM14A, originally identified in 1998 as an mRNA-binding protein in salamander oocytes
[28], was implicated in a 2012 report in innate immune signaling upon RNA and DNA virus
infections [22]. Using SeV as an example of an RNA virus and herpes simplex virus-1 (HSV-1)
as an example of a DNA virus, the 2012 study showed that LSM14A enhanced ISRE activity in
response to virus infection. Consistent with this, we observed a dose-dependent effect of
LSM14A on SeV-induced ISRE activation in 293T cells. However, when LSM14A is cleaved by
2Apro, it can no longer mediate SeV-induced ISRE activation, indicating a loss of function.
LSM14A is a 463 aa protein with an N-terminal LSm domain of 76 aa (aa 1–76) followed by an
intrinsically unstructured region of around 200 aa and then two C-terminal motifs, namely a
DFDF box (aa 291–316) and an FDF_TFG box (aa 361–397) [22]. The C-terminal region of
panel) or infected with SeV (right panel) for 24h followed by luciferase assay. The FLuc/RLuc ratio was calculated and plotted as fold-increase over the minimum
amount of vector plasmid used (6.25 ng). (B) LSM14A cleavage fragments do not activate ISRE. The reporter assays with the indicated LSM14A mutants were
performed similarly as in A. The DNA concentrations of 6.25, 12, 25, and 50 ng/well were used. (C) TEVP-mediated cleavage of LSM14A blocks its ability to activate
ISRE. The 293T cells containing dox-inducible TEVP and expressing the ISRE-FLuc and RL-RLuc reporters were transfected with 12.5 ng/well, 25 ng/well, or 50 ng/well
LSM14A-TEVP plasmid followed by SeV infection. The indicated amount of doxycycline was added to the culture medium 24h prior to DNA transfection and kept for
the entire experiment. The reporter assay was performed as described in A. (D) LSM14A requires RIG-I and MAVS for its function. The 293T cells knocked out for the
indicated genes were used for the reporter assays as described in A (top panel). 50 ng/well DNA was used. The cells were tested for the expression of the indicated
proteins. For detection of RIG-I and MDA5, the cells were exposed to 5 nM IFN-2a alpha for 48h. (E) MAVS does not require LSM14A for its innate immune function.
The 293T cell clones expressing or lacking LSM14A were transfected with 12.5 ng/well MAVS and tested for the activation of ISRE as in A. This experiment was
performed in the absence of SeV infection. KO-pool was generated by mixing the 293T cell clones that were confirmed for the loss of LSM14A. (F) SeV can activate
ISRE in the absence of LSM14A. The 293T cell clones used in E were infected with SeV and the ISRE reporter activity was measured as in A. For all experiments, the data
are presented as mean +/- standard deviation for triplicate samples.
https://doi.org/10.1371/journal.ppat.1008927.g007
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the protein is essential for RNA-binding and p body localization [22, 29], two characteristics
that are believed to be important for LSM14A antiviral immune activity. This region alone
however cannot mediate immune signaling and requires the presence of the N-terminal LSm
domain for activity. In line with this, when the N- and C-terminal domains of LSM14A are
separated by enteroviral cleavage, the protein becomes inactive. Unfortunately, we could not
show the direct relevance of LSM14A to enterovirus infection due to several biological and
technical limitations, such as the robustness of virus infection in most cell lines, redundancy in
the innate immune pathways, and cleavage of several other immune components by this group
of viruses. For instance, enteroviruses are known to target RIG-I [30] and MAVS, the two pro-
teins our knockout experiments suggested are essential for LSM14A activity (Fig 7D). This
diminished the utility of typical overexpression and knockout strategies to decipher the func-
tion of LSM14A during enterovirus infection.
The N-terminomics approaches simultaneously reveal the identity of the proteins being
cleaved and the exact site within a protein where the cleavage occurs. This allowed us to search
for proteins directly targeted by enteroviral proteases. We first generated a list of candidates
that were found cleaved in at least two of the three CVB3-infected replicates but in no unin-
fected replicate and then cross-referenced this list with the consensus sequence motifs that
enteroviral proteases are known to target. This yielded a number of proteins from various cel-
lular processes, many of which have been previously implicated in enterovirus replication. For
example, proteins essential for various steps during host gene expression, autophagy, and anti-
viral immune signaling were identified. Similarly, several components of the cytoskeleton,
cytoplasmic ribonucleoprotein granules, and the nuclear pore complex were among the pro-
teins targeted for cleavage. Enteroviruses are well known for reducing new protein synthesis
by translational shut off early in infection, as confirmed by the cleavage of eIF4G at just 2 h.p.i.
Our finding that proteolysis targets numerous additional factors involved in gene expression
emphasizes the way these viruses remodel the cell for their benefit. Importantly, western blot
analysis of infected cells confirmed all the cleavages tested, and the in vitro assay further vali-
dated that the cleavages were mediated by the viral proteases. It should however be noted that
the in vitro assay does not completely rule out the possibility of a cleavage being mediated by a
host protease. It is conceivable that mixing an enteroviral protease with the HeLa cell lysate
stimulated a host protease that then targeted its substrates.
As the virus-infected cells approached complete cytotoxicity, the numbers of cleaved pro-
teins substantially increased. This was likely the cumulative effect of the high levels of viral pro-
teases per cell and the loss of subcellular compartmentalization, allowing the viral proteases to
contact more cellular proteins. Also, extensive changes in the intracellular milieu might result
in the activation of host proteases, and indeed we observed a surge of caspase activity as CPE
became evident. Inferring that late-stage cleavages are likely to be non-specific, we included
only those proteins cleaved early in infection when listing high-confidence targets. It is worth
noting, however, that several functionally important cleavages have been reported to occur late
in enterovirus infection. For example, many proteins that enteroviruses recruit at early stages
of infection but need to eliminate at later stages are removed by protease-mediated cleavage
[25]. Also, whereas in most cases a cleavage renders the substrate non-functional, there are
instances where a cleavage endows the protein with a new function beneficial for the virus. For
example, RIP3, a kinase that regulates autophagy and orchestrates necrotic cell death, is an
essential host factor for the early phase of CVB3 replication. Later in infection, RIP3 is cleaved
by CVB3 3Cpro, which ablates its ability to mediate necrotic cell death and generates a C-termi-
nal cleavage product that is utilized by CVB3 to induce a non-necrotic form of cell death [25].
While we focused on early cleavages in this study, understanding late stage cleavages could be
equally important.
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The advent of various N-terminomics approaches has spurred interest in the role of viral
proteases in virus-host interactions. Recently, Jagdeo et al., used TAILS, another N-terminomics
approach, to inventory cellular proteins cleaved by the enteroviral 3Cpro [21]. They mixed HeLa
or HL-1 (murine cardiac muscle cells) cell lysates with the purified viral protease from CVB3 or
PV and identified proteins that were cleaved by the wild-type but not catalytically inactive
3Cpro. This yielded a list of 34 high-confidence substrates, seven of which the authors subse-
quently validated in virus-infected cells. Interestingly, six of these seven substrates were present
in our dataset, and importantly, for one substrate, RIPK1, where the authors saw discrepancy
between the TAILS and western blot results, the subtiligase method we employed identified the
cleavage site that matched the products observed in western blot. This emphasizes the impor-
tance of applying N-terminomics approaches on virus-infected cells rather than protease-mixed
cell lysates, as the former is likely to yield more accurate and complete information about host
targets and sites of cleavage. Another advantage of using a virus infection system is that it allows
for the identification of temporally and spatially regulated cleavage events.
In all, this report provides the first comprehensive view of proteolysis in enterovirus-
infected cells and adds LSM14A to the growing list of host proteins that enteroviruses target
for cleavage to generate a virus-friendly environment. The inventory of candidate proteins pre-
sented in this study provides a foundation for future investigations into the complex interplay
between enteroviruses and their host cells, and the approach and pipeline can be applied to
define the proteolysis landscape of any virus-host encounter.
Materials and methods
Cells and viruses
Human cervical carcinoma HeLa cells (ATCC CCL-2), human embryonic kidney HEK293T
cells (ATCC CRL-3216), human muscle rhabdomyosarcoma RD cells (ATCC CCL-136), and
human neuroblastoma SK-N-SH cells (ATCC HTB-11) were maintained in Dulbecco’s mini-
mum essential medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Human
colorectal adenocarcinoma Caco-2 cells (ATCC HTB-37) were grown in DMEM containing
20% FBS. 293T cells deficient for RIG-I, MDA5, MAVS, and STAT1 have been previously
described and were kindly provided by Veit Hornung (Universitat Bonn, Germany) [31].
For neural progenitor cells (NPC), we first differentiated the human embryonic stem cells
(hESC) into neuroectoderm cells using the dual SMAD inhibition method (Chambers et al.,
Nature Biotechnology. 2009). Briefly, hESC were dissociated into single cells using Accutase
and plated onto Matrigel-coated plates in the presence of 10 μM ROCK inhibitor (Y-27632) to
achieve the confluence of approximately 90% the next day. Differentiation was induced with
SRM (Knockout DMEM/F12 containing 15% knockout serum replacement (KOSR) and 1%
GlutaMax) supplemented with 10μM SB431542 and 200nM Noggin for five to seven days.
Confluent ectoderm cells were passaged and maintained for one more week in the induction
medium containing dual SMAD inhibitors. Derived NPC were then maintained in neural pro-
genitor medium (Knockout DMEM/F12 containing 2% StemPro Neural Supplement and 1%
GlutaMax) supplemented with 20 ng/ml bFGF and 20 ng/ml EGF. NPC cultures were fed
fresh medium daily. The reagents used for stem cell differentiation were obtained from the fol-
lowing vendors: Matrigel (# 356230), Corning; ROCK inhibitor Y-27632 (# 72308), STEM-
CELL Technologies; KOSR (# 10828028), Life Technologies; GlutaMax (# 35050–061), Life
Technologies: SB431542 (# 1614), Tocris Bioscience; Noggin (# 120-10C), Peprotech; StemPro
Neural Supplement (# A10508-01), Life Technologies; bFGF AA 10–155 (# PHG0024), Life
Technologies; animal-free human EGF (# AF-100-015), Peprotech; and knockout DMEM/F-
12 (# A1370801), Life Technologies.
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With the exception of EV71, all enteroviruses used in this study were rescued from infec-
tious cDNA clones obtained from various investigators: pMKS1-GFP [32] (referred to as
eGFP/CVB3 in this paper) was obtained from Dr. J. Lindsay Whitton of the Scripps Research
Institute, La Jolla; poliovirus (pT7-Manony) [33] and human enterovirus 70 (pDNE9) [34]
from Dr. Vincent Racaniello of Columbia University, New York; and human rhinovirus A16
strain (pA16) [35] from Dr. Ann Palmenberg of the University of Wisconsin, Madison.
Human enterovirus 71 was obtained from BEI resources (cat. no. NR-471). The Cantell strain
of the Sendai virus (SeV) used for innate immune induction experiments was generated in the
laboratory of Dr. Adolfo Garcia-Sastre of The Icahn School of Medicine at Mount Sinai, New
York, by inoculation into the allantoic cavity of 10-day-old embryonated chicken eggs. Follow-
ing incubation at 37˚C for 48h, allantoic fluid was harvested and titrated by hemagglutination
of chicken red blood cells. GFP-tagged version of the VEEV vaccine strain TC83 (VEEV-GFP)
[36] was from Ilya Frolov of the University of Texas, Galveston, and the GFP-tagged VSV
(VSV-GFP) [37] was from John Rose of the Yale University, New Haven.
Virus infections
Large-scale experiments: For each infection experiment, HeLa cells were plated into twenty-
four 150-cm dishes (six dishes for each of the four time points) at the density of 10 million
cells per dish. The next day, we infected the cells with the virus at a multiplicity of infection
(m.o.i.) of 5 plaque-forming units (PFU)/cell. Since eGFP/CVB3 did not yield plaques, we
could not calculate m.o.i. for this virus. Therefore, we optimized the infection conditions for
eGFP/CVB3 using different dilutions of the virus stock and selecting the dilution that yielded
100% GFP-positive cells at 4 h.p.i. For infection, the virus was diluted in 5 ml of opti-MEM
and adsorbed to the cell monolayer at 37˚C for 1h. The virus inoculum was then removed and
25 ml of DMEM/10% FBS was added to each dish. The cells were harvested at the indicated
times determined by prior small-scale infection experiments described below. For each time
point, we divided six dishes into three sets of two dishes each and pooled the cells from each
set to obtain the total of three replicates. The uninfected cells were harvested concomitant with
the last infection time point. To harvest, we scraped the cells into enzyme-free cell dissociation
solution (Millipore: #S-014-C) and pelleted them by centrifugation at 1,000 xg for 5 min. The
cell pellets were then flash frozen in liquid nitrogen and stored at -80˚C.
Small-scale experiments: To determine the optimal m.o.i. and times of harvest for large-
scale experiments, we seeded HeLa cells into 24-well plates at a density of 175,000 cells per well
and allowed them to grow overnight at 37˚C. We infected the cells at the m.o.i. of 1, 5, or 10 by
first diluting the virus in 100 μl of opti-MEM and then incubating the cells with this inoculum
at 37˚C for 1h. The virus inoculum was then removed and fresh DMEM/10% FBS medium
was added. The cells were then fixed at various times after infection with 4% paraformaldehyde
(PFA) and stained with antibodies against viral antigens.
Antibodies and chemicals
The antibodies used for immunofluorescence include anti-PV 1 antibody clone
583-G8-G2-A4 (Millipore: #MAB8560), anti-EV-D70 antibody clone 74-5G (Millipore;
#MAB843), anti-EV-A71 antibody (GeneTex; #GTX132339), and anti-rhinovirus antibody
clone R16-7 (LifeSpan BioSciences; #LS-C200976), anti-LSM14A antibody (Bethyl Laborato-
ries; #A305-103A). Most antibodies for western blot were purchased from Bethyl Laboratories.
These included rabbit polyclonal antibodies against ARFP1 (#A304-676A), AR14B (#A302-
233A), CAPR1 (#A303-882A), CBX8 (#A300-882A), CD2AP (#A304-728A), CHERP (#A304-
621A), DBNL (#A303-351A), DDX6 (#A300-461A), DHX9 (#A300-855A), EP300 (#A300-
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358A), F120A (#A303-889A), HNRPM (#A303-910A), HTF4 (#A300-754A), HTSF1 (#A302-
023A), I2BP2 (#A303-190A), LSM14A (#A305-103A), MAPK3 (#A304-305A), MATR3
(#A300-591A), MAVS (#A300-782A), NEDD1 (#A304-545A), NHEJ1 (#A300-730A), NUFP2
(#A301-600A), NUP98 (#A301-786A), PP6R1 (#A300-968A), PRP17 (#A303-700A), RBP56
(#A300-309A), SP130 (#A302-491A), and SRPK2 (#A302-467A). The following antibodies
were purchased from Proteintech: CT2NL (#25523-1-AP), PANX1 (#12595-1-AP), SHRM1
(#18218-1-AP), TLE3 (#11372-1-AP), and USO1 (#13509-1-AP).
The antibodies purchased from the Cell Signaling Technology include anti-BRD4 rabbit
monoclonal (#13440), anti-eIF4G rabbit polyclonal (#2498), anti-FOXK1 rabbit polyclonal
(#12025), anti-HNRPD rabbit monoclonal (#12382), and anti-STAT3 rabbit polyclonal
(#9132). Additional primary antibodies include anti-DSRAD mouse monoclonal (Santa Cruz
Biotechnology; #sc271854), anti-SCRIB rabbit polyclonal (GeneTex; #GTX107692), anti-HA
rabbit polyclonal (Abcam; #ab9110), anti-V5 mouse monoclonal (ThermoFisher Scientific;
#MA5-15253), and IRDye 800CW-conjugated anti-streptavidin antibody (Rockland Immuno-
chemicals; S000-31). The secondary antibodies used for western blot included IRDye 680RD
goat anti-mouse (LI-COR; 926–68070) and IRDye 800CW goat anti-rabbit (LI-COR; 926–
32211).
The following chemicals were purchased from Sigma: Acetonitrile (#271004), TCEP
(#75259), iodoacetamide (I1149), AEBSF (#A8456), and PMSF (#P7626). E-64 protease inhibi-
tor (#324890) and Z-VAD pan-caspase inhibitor (#219007) were purchased from EMD Milli-
pore. Sequencing grade trypsin was purchased from Promega (#V5113) and Lysyl
endopeptidase from Wako (#125–05061).
Plasmids
LSM14A cDNA was PCR amplified from the total HeLa cell cDNA and appended at its 5’ and
3’ ends with the V5 and HA tags, respectively. The PCR primers were engineered to introduce a
BamH1 cleavage site upstream of the V5 tag and an Nhe1 cleavage site downstream of the HA
tag. Using these cleavage sites, we cloned LSM14A cDNA into the pLOC lentiviral vector and
pcDNA3.1 expression plasmid to obtain pLOC-LSM14A and pcDNA3.1-LSM14A, respectively.
For LSM14A cleavage-defective mutants, we replaced glycine at position 147 with alanine or
glutamic acid by overlapping PCR. The N-terminal V5-tagged ubiquitin (Ubi) was fused with
amino acid 147–463 of LSM14A to obtain pV5-Ubi-LSM14A. The pISRE-FLuc plasmid con-
taining ISRE-driven Firefly luciferase reporter was from Stratagene (#219089) and pRL-RLuc,
containing CMV promoter-driven Renilla luciferase reporter, was generated by modifying the
pRL-HL plasmid, generously provided by Dr. Stanley Lemon [38]. The small guide RNA
(sgRNA) plasmid pSpCas9(BB)-2A-Puro (PX459) (Addgene # 481239) was a gift from Feng
Zhang. We designed three sgRNA for CRISPR knockout of LSM14A using crispor.tefor.net:
sgRNA1 (exon1), 5’-AGCGGGGGCACCCCTTACAT-3’; sgRNA2 (exon 2), 5’-GGTGGTA
TTGGACGATCTGT-3’; and sgRNA3 (exon 4), 5’-TTACCCCAAAGTAGTGCGGT-3’. The
sgRNA were then cloned into PX459 plasmid for subsequent transfection into cells.
Production and purification of recombinant proteins
TEV protease. The recombinant TEV protease was produced in Escherichia coli as previ-
ously described [39]. Briefly, a His6-tagged TEV S219V mutant was cloned into pET vector
and transformed into BL21 DE3 cells. The next day, we inoculated one bacterial colony into 50
ml of LB medium and grew overnight at 37˚C. Twenty-four hours later, 2.5 ml from the over-
night bacterial culture was transferred into 1L of fresh LB medium and the cells were grown in
a shaking incubator at 37˚C until OD600 reached ~ 0.5. The cells were chilled on ice, and the
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protein expression was induced with 1mM IPTG. After shaking at 30˚C for 4h, the cells were
harvested by centrifugation. Cell pellets were resuspended in the storage buffer (20% sucrose
and 20 mM Tris pH 8), flash frozen in liquid nitrogen, and stored at -80˚C.
To purify the TEV protease, the cells were lysed by sonication in the presence of 500 mM
NaCl, 20 mM Na/K phosphate, 1 mM PMSF, 0.5% IGEPAL (octyl-phenyl-polyethylene gly-
col), 15 mM imidazole, 1 mM ß-ME (ß-mercaptoethanol), 50 μg/ml lysozyme, 2 μg/ml DNase
I, and 2 μg/ml RNase A. The lysate was centrifuged at 40,000 xg at 4˚C for 1h to remove the
insoluble material. The protein contained in the supernatant was captured on Ni-NTA agarose
beads (Qiagen) by incubating the supernatant with the beads for 1h at 4˚C. The beads were
then loaded on an Econo-Pac column (Bio-Rad) and washed with 25 column volumes of wash-
ing buffer (500 mM NaCl, 20 mM Na/K phosphate, 15 mM imidazole, 20 mM Tris pH 8, and
1 mM ß-mE). The bound protein was eluted off of the beads with elution buffer (500 mM
NaCl, 20 mM Na/K phosphate, 250 mM imidazole, 20 mM Tris pH8, and 1 mM ß-ME) and
further purified by gel-filtration using a HiPrep 26/60 Sephacryl S-200 HR column (GE
Healthcare).
Subtiligase. Bacillus subtilis BG2864 bacteria, containing a plasmid carrying subtiligase,
were grown overnight at 37˚C in 2X TY medium containing 12.5 μg/ml chloramphenicol. The
culture was centrifuged at 4500 xg for 15 min at 4˚C and the bacterial pellet was discarded. The
supernatant was placed on a magnetic stirrer and the protein in the supernatant was precipi-
tated by slow addition of ammonium sulfate at 4˚C. After 1h of mixing, the protein was pel-
leted by centrifugation at 10,000 xg for 30 min at 4˚C. The pellet was dissolved in a buffer
containing 5 mM DTT and 25 mM sodium acetate pH 5.0 followed by addition of three vol-
umes of ethanol to obtain the final concentration of 75%. Following another 30-min mixing
on a stir plate, the solution was centrifuged at 5000 xg for 15 min at 4˚C. The protein pellet was
resuspended in the above buffer (5 mM DTT and 25 mM sodium acetate pH 5.0) and dialyzed
against 9L of the same buffer overnight at 4˚C. After dialysis, the protein was sequentially puri-
fied with ion exchange and gel filtration columns (HiTrap SP HP 5 ml and Superdex 200 10/
300GL; GE Healthcare). The concentration of the purified protein was set at 100 μM and
stored at -80˚C.
CVB3 proteases. For wild-type 2Apro, wild-type 3Cpro, and C147A 3Cpro, the BL21 (DE3)
T1R pRARE2 bacteria containing the plasmids with His-tagged protease constructs were
grown overnight in the presence of 100 μg/ml kanamycin and 34 μg/ml chloramphenicol.
When OD600 reached 0.3, the protein expression was induced by overnight treatment with 0.5
mM IPTG. For 2Apro, we used autoinduction media (Thermo: K6803) and also added 1 μM
ZnCl2 to facilitate protein folding. The cultures were then centrifuged at 4500 xg for 10 min
and the pellets were lysed by pulse sonication in the presence of 100 mM HEPES, 500 mM
NaCl, 10% glycerol, 10 mM imidazole, and 0.5 mM TCEP, pH 8.0. The lysates were centri-
fuged at 49,000 xg for 20 min and the supernatants were filtered through 0.45 μm filters. The
samples were then loaded onto ÄKTA Xpress (GE Healthcare) and purified first with an
IMAC column 5 ml HisTrap HP (GE Healthcare) and then with a gel filtration column
HiLoad 16/60 Superdex 75 (GE Healthcare). As our constructs contained the TEV protease
cleavage site cloned between the His tag and the N-terminal end of the CVB3 proteases, we
removed the tag by incubating the samples with TEV protease at a protease-to-protein ratio of
1:25 at room temperature for 2h. The cleaved His tag was then removed from the protein
preps by passing the samples through the HisTrap HP column. The flow through was collected
and concentrated to 1 mg/ml in the storage buffer (25 mM HEPES pH 7.5, 140 mM NaCl, 2
mM TCEP, 10% glycerol) followed by lyophilisation and storage at -80˚C.
For C110A 2Apro, the His-tagged protease was cloned into pBVboostFGIIWPRE C43 plas-
mid and transformed into BL21 DE3 bacteria. The bacteria were grown in 5 mM glucose and
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7 μg/ml gentamycin to the OD600 of 0.4 and protein expression was induced by overnight
treatment with 0.1 mM IPTG at 28˚C. The bacterial culture was then centrifuged at 4500 xg
for 10 min and lysed by sonication in the binding buffer (50 mM Tris pH 8, 0.5 M NaCl, 10
mM imidazole) containing 30 μg/ml lysozyme. The cell lysate was centrifuged at 10,000 xg for
20 min at 4˚C and the supernatant was incubated with Ni-NTA agarose beads. The captured
protein was eluted off the beads using 50 mM Tris pH 8, 0.5 M NaCl, and 500 mM imidazole
followed by removal of imidazole with VivaSpin Turbo 10K centrifugal filter (Sartorius). The
protein was further purified by anion exchange chromatography using Q Sepharose Fast Flow
(GE Healthcare), lyophilized in the storage buffer (25 mM HEPES pH 8, 140 mM NaCl), and
stored at -80˚C.
Preparation of TEVest4
The TEVest4 peptide is an amine terminal biotinylated peptide comprised of the sequence:
Biotin-eAhx-eLys-Gly-Gly-Thr-Glu-Asn-Leu-Tyr-Phe-Gln-Abu-Glc-Arg-NH2. The peptide
was synthesized by solid-state peptide synthesis with slight modifications from the original
protocol [40]
N-terminal peptide isolation
For labeling, the frozen cell pellets were lysed by sonication in a buffer containing 1% SDS, 100
mM bicine pH8.0, 5 mM EDTA, 50 μM z-VAD-fmk, 50 μM E-64, 500 μM AEBSF, and 50 μM
PMSF. The lysates were first passed through QIAshredders (Qiagen; #79654) to shred the
remaining nucleic acids and then through detergent removal columns (ThermoFisher Scien-
tific; #87777) to remove SDS. The total cellular protein in all samples was set at 15 μg/μl to
obtain a total of 3 mg protein in a 200-μl volume. The lysates were incubated at room tempera-
ture for 1h with a biotinylated peptide ester (TEVest4; 10 mM stock in DMSO) and purified
recombinant subtiligase (100 mM stock; see below) to obtain the final concentrations of 1 mM
and 1 μM, respectively. The unincorporated peptide esters were removed by acetonitrile
precipitation.
The air-dried protein pellets were then dissolved in 6M guanidine hydrochloride (GnHCl)
containing 100 mM bicine pH 8.0 and 10 mM TCEP. The samples were incubated at 95˚C
until the pellets were completely dissolved. This was followed by an alkylation reaction, where
the samples were incubated with 10 mM iodoacetamide (IAM) at room temperature for 45
min in the dark. The IAM reaction was then quenched with 10 mM DTT and biotinylated pro-
teins were captured overnight on immobilized NeutrAvidin agarose beads (ThermoFisher Sci-
entific; #29202).
The beads were washed five times with a wash buffer containing 4M GnHCl and 100 mM
bicine, and digested overnight at 37˚C in digest buffer (100 mM ammonium bicarbonate, 1M
GnHCl, 100 mM NaCl, 5 mM CaCl2) containing a mixture of 3 μg sequence-grade trypsin and
1.5 μg lysyl endopeptidase. Following digestion, the beads were washed five times with wash
buffer and resuspended in TEV protease buffer containing 100 mM ammonium bicarbonate,
1 mM EDTA, and 2 mM DTT. Peptides were released by digestion with 40 μg TEV protease
for 6h at room temperature and desalted with C18 Empore (3M) StAGE tips, prepared in
house [41].
LC-MS/MS
We dried the desalted samples and solubilized in 2% acetonitrile and 2% formic acid prior to
analysis by one-dimensional reversed-phase nano-LC-MS/MS (Q-Exactive Plus, Thermo-
Fisher Scientific). For reversed-phase liquid chromatography (LC), we used C18 columns of 12
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cm length and 75 μm internal diameter packed with beads of 3 μm particle size (Nikkyo Tech-
nologies, Japan), and delivered an 80 min gradient increasing from 5% B/95% A (A: 0.1% for-
mic acid in water, B: 0.1% formic acid in 80% acetonitrile) to 40% B/60% A at a flow rate of
300 nL/min (Dionex 3000, ThermoFisher Scientific). Peptides were concentrated using a trap
column (ThermoFisher Scientific, #164564-CMD) prior to separation. MS1 was scanned from
m/z 300 to m/z 1400. For HCD MS/MS acquisition, a resolution of 17,500 was used with Auto
Gain Control of 5e5 and a maximum injection time of 100 ms. The lowest mass was set at m/z
140. For the Q-Exactive Plus mass spectrometer, we subjected the 20 most abundant multiply
charged (2+, 3+, 4+, and 5+) peptides to tandem MS. Primary data will be made available
upon request.
Interpretation of MS/MS spectra
LC-MS/MS data were analyzed using Proteome Discoverer 2.3.0.523 software combined with
MASCOT v. 2.3. Tandem MS data were queried against the UniProt human proteome (Sep-
tember 2018 release) concatenated with common contaminants and virus proteome
sequences. The minimal peptide length was set at 7 amino acids. The filter of 5% false discov-
ery rate (FDR), calculated by Percolator [42], was applied. Semi-tryptic digestion search con-
straints were used. All cysteines were treated as being carbamidomethylated. Methionine
oxidation and N-terminal C4H7NO (α-aminobutyric acid, Abu), the latter resulting in a mass
increase of 85.052764 Da, were allowed as variable modifications. Peptide intensities and spec-
tral counts were used for quantification.
Bioinformatic analysis
Qualitative analysis was performed to identify proteins cleaved in virus-infected cells. For this,
we first required that the peptides must be Abu-labeled, identified with high confidence in at
least two of the infected replicates, and absent in uninfected cells. Next, we collected gene iden-
tifiers assigned to cleaved peptides to create lists of genes with products cleaved following
infection. We excluded non-human proteins. To identify proteins that are commonly cleaved
among enteroviruses, we used the following filters: 1) A peptide must be identified with high
confidence for at least one virus, 2) the peptide must be present in a minimum of two infected
replicates for at least two viruses, and 3) the peptide must not be detected in any uninfected
replicate. To account for exopeptidase nibbling (ragging), we wrote, validated, and imple-
mented a script in R allowing for removal of those peptides from our final analyses that pre-
sumably arose from exopeptidase activity. We then input the final list of proteins into the
“Search Tool for Recurring Instances of Neighboring Genes” (STRING) at https://string-db.
org [43]. Only those interactions meeting the “highest confidence” criteria in the STRING
database were included in the resulting interaction network. This network was then exported
and visualized in Cytoscape [44], and clusters within the network were identified using the
MCODE clustering algorithm [45] as implemented in the Cytoscape plugin “clusterMaker2”
[46]. We functionally profiled the clusters that contained more than five proteins using GO
(gene ontology) enrichment analysis as implemented in the “clusterProfiler” R package (ver-
sion 3.12.0) [47]. GO terms with FDR-adjusted enrichment p-values less than 0.05 were con-
sidered significant. While choosing proteins for validation by western blot, we required that
the P1 and P1´ amino acids match with the enteroviral protease cleavage site specificity.
In vitro cleavage assay
HeLa cells were lysed by sonication in a buffer containing 100 mM bicine pH 8.0, 140 mM
NaCl, 5 mM DTT, and 0.1% Triton-X. The lysate was then centrifuged at ~21,000 xg for 20
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min at 4˚C to pellet down the insoluble material. The protein concentration was measured by
BCA assay using Pierce BCA Protein Assay Kit (ThermoFisher Scientific; # 23225) and set at
2 μg/μl. For the CVB3 2Apro cleavage assay, we mixed 100 μl cell lysate (200 μg protein) with
1 μg of wild-type or catalytically inactive protease to obtain a protease-to-protein ratio of
1:200. For the CVB3 3Cpro cleavage assay, we used a protease-to-protein ratio of 1:2. These
ratios were determined by pilot experiments where cell lysates and proteases were mixed in
different proportions and cleavage of known substrates was used as a guide. The digestion
reaction was carried out at 37˚C for 3h, followed by addition of a sample loading dye and 10
min incubation at 70˚C. Protein cleavages were tested by western blot.
Generation of LSM14A knockout cells
293T cells were transfected with the PX459 plasmid containing LSM14A sgRNA using Lipofec-
tamine 2000 DNA transfection reagent (ThermoFisher Scientific, #11668030). We prepared
three cell populations; first, transfected with empty PX459 as a control; second, transfected
with the combination of sgRNA 1 and 2; and third, with the combination of sgRNA 2 and 3.
The transfected cells were exposed to 2.5 μg/ml puromycin for 48h starting at 36h post-trans-
fection and then recovered for 3 days in puromycin-free medium. The single cell clones were
obtained by seeding the cells into 96-well plates at a density of 0.7 cells per well. The resulting
cell clones were screened for the expression of LSM14A by western blot.
Luciferase assay
For dual luciferase assays, cells were seeded into 48-well plates at a density of 30,000 cells per
well in 250 μl volume and grown overnight at 37˚C. The next day, the cells in each well were
transfected with 50 ng of pISRE-FLuc plasmid DNA and 2.5 ng of pRL-RLuc plasmid DNA
along with various concentrations of the genes of interest (for example, pcDNA3.1-LSM14A,
pcDNA3.1-MAVS, or pcDNA3.1-GFP herein referred to as “vector”). XtremeGENE 9 (Roche;
# 06365787001) was used as a DNA transfection reagent. The next day, the cells were infected
with SeV for 24h and lysed with 1X passive lysis buffer (Promega) according to the manufac-
turer’s recommendations. Firefly and Renilla luciferase activities were measured with the
Dual-Luciferase Reporter Assay System (Promega) using a Lumat LB9507 Luminometer (EG
& G Berthold, Bad Wildbad, Germany).
Supporting information
S1 Fig. Optimization of subtiligase labeling. (A) SDS lysis yielded better results than Triton-
X lysis. HeLa cells infected with eGFP/CVB3 were lysed in either 1% Triton-X or 1% SDS. The
experiment was performed in triplicate. All SDS lysates were sonicated, while out of the three
Triton-X lysates, two were sonicated and one was left unsonicated. The western blot was per-
formed with anti-histone H3 and anti-GFP antibody. (B) SDS depletion before labeling was
necessary for subtiligase reaction. The HeLa cell lysates were prepared with either 1% Triton-X
(single) or 1% SDS (triplicate). Of the three SDS lysates, two were subjected to SDS removal
before subtiligase labeling while one was labeled in the presence of SDS. The Triton-X lysate
contained the detergent during labeling. The labeling efficiency was determined by western
blot with streptavidin. In parallel, the western blot for histone H3 and GFP was also per-
formed.
(TIF)
S2 Fig. Subtiligase labeling of eGFP/CVB3-infected HeLa cells. (A) HeLa cells were infected
with eGFP/CVB3, and the infection was monitored by GFP detection at the indicated times.
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DAPI was used for nuclear staining. The bright field (BF) images show progressive cell
rounding with infection. (B) HeLa cells infected with eGFP/CVB3 for 2, 4, or 6h, or left unin-
fected, were lysed in 1% SDS. The lysates were then depleted of SDS and either subjected to
western blot to detect GFP and actin (left panel) or incubated with subtiligase and biotinylated
peptide. The labeling efficiency was determined by western blot with streptavidin. The two dif-
ferent exposure times are shown.
(TIF)
S3 Fig. Cleavages at CVB3 2Apro motifs. The CVB3 2Apro preferably cleaves proteins at Y-G,
T-G, F-G, V-G, and A-G pairs. We calculated the frequency of these cleavages at different
times post-infection. The results of Y-G and T-G are shown in Fig 1D, while the rest are
shown here.
(TIF)
S4 Fig. Validation of protein cleavages identified by subtiligase labeling. HeLa cells were
infected with eGFP/CVB3 and lysed at 0, 2, 3, 4, 5, and 6 h.p.i. followed by western blot analysis
of the indicated proteins. An equal amount of total protein, as quantified by the BCA assay, was
loaded for each time point. The GFP expression was used to monitor the progression of infec-
tion (last panel). The black solid arrows indicate the full-length protein, while the cleavage prod-
ucts are shown with red dotted arrows. Some of the western blot images are shown in Fig 2.
(TIF)
S5 Fig. Validation of cleavage targets by overexpression followed by western blot. (Top
panel) General schematics of protein tagging with V5 at the N-terminal end and HA at the
C-terminal end. (Bottom panel) HeLa cells transduced to stably express the indicated doubly
tagged proteins were infected with eGFP/CVB3 for 4h or 6h, or left uninfected followed by
detection of cleavage by western blot. The blots were probed with mouse anti-V5 and rabbit
anti-HA antibodies and detected with IRDye 680RD goat anti-mouse IgG (red channel) and
IRDye 800CW goat anti-rabbit IgG (green channel). The full-length protein is indicated with
black solid arrows, while the cleavage products are indicated with red dotted arrows.
(TIF)
S6 Fig. In vitro cleavage assay of the identified proteins. HeLa cell lysates (200 μg protein) were
incubated with CVB3 2Apro or its catalytically inactive mutant C110A (1 μg), or CVB3 3Cpro or its
catalytically inactive mutant C147A (100 μg) at 37˚C for 3h and analyzed by western blot. Lysates
from the uninfected and eGFP/CVB3-infected HeLa cells were included as positive controls. The
full-length protein is indicated with black solid arrows, while the cleavage products are indicated
with red dotted arrows. Some of the western blot images are shown in Fig 3.
(TIF)
S7 Fig. Growth kinetics of enteroviruses in HeLa cells. The cells infected with PV (poliovi-
rus), HRV (human rhinovirus A16), EV70 (enterovirus D-70) and EV71 (enterovirus A-71)
were fixed in 4% PFA at the indicated times post-infection and analyzed for the expression of
viral capsid proteins using antibodies specific to each virus (Material and Methods).
(TIF)
S8 Fig. Conservation of cleavage targets across enteroviruses. The list of proteins targeted
for cleavage in eGFP/CVB3-infected HeLa cells were checked for their presence in the proteo-
mics dataset of the indicated viruses. The tiles, indicating the detection of the proteins shown
on left, are color-coded for visual clarity.
(TIF)
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S9 Fig. Validation of proteins targeted by multiple enteroviruses. HeLa cells infected with
CVB3 (eGFP/CVB3), PV (poliovirus type 1), HRV (human rhinovirus A16), EV70 (enterovi-
rus D-70), EV71 (enterovirus A-71), VEEV (Venezuelan equine encephalitis virus) or VSV
(vesicular stomatitis virus) were lysed at the indicated times, and equal amounts of total pro-
tein were subjected to western blot with the indicated antibodies. The black solid and red dot-
ted arrows indicate the full-length protein and the cleavage products, respectively. Some of the
western blot images are shown in Fig 5.
(TIF)
S10 Fig. Testing protein cleavages in multiple cell types. HeLa (cervical epithelial) cells
infected with eGFP/CVB3 and PV for 6h, Caco-2 (intestinal epithelial) cells infected with
eGFP/CVB3 and PV for 8h, NPC (neural progenitor cells) infected with eGFP/CVB3 and PV
for 8h, RD (rhabdomyosarcoma) cells and SK-N-SH (brain epithelial) cells infected with PV
for 8h were analyzed for the cleavage of indicated proteins. The full-length protein is shown
with black solid arrows, while the cleavage products with red dotted arrows.
(TIF)
S11 Fig. LSM14A is cleaved in stem cell-derived neurons infected with enteroviruses.
Immunofluorescence images: embryonic stem cell-derived neurons were stained for TUJ1, a
neuron-specific protein (left panel), and with DAPI as a nuclear stain (middle panel). The
right panel shows the merged image. Western blot: The neurons were infected with eGFP/
CVB3 or PV for 7h followed by western blot with anti-LSM14A antibody. The solid black
arrow shows the full-length protein while the red dotted arrow indicates the C-terminal cleav-
age product.
(TIF)
S12 Fig. MAVS activates ISRE in the absence of SeV infection. 293T cells, seeded into
48-well plates at a density of 30,000 cells/well, were transfected with the ISRE-FLuc and
RL-RLuc reporter plasmids along with GFP plasmid (vector) or increasing concentrations of
MAVS plasmid (6.25 and 12.5 ng/well). Twenty-four hours later, the cells were either left unin-
fected or infected with SeV for 24h followed by the reporter assays as described in Fig 7A. V,
vector.
(TIF)
S13 Fig. Characterization of LSM14A-TEVP. (A) 293T cells were transfected with the indi-
cated concentrations of the vector, LSM14A-WT, or LSM14A-TEVP plasmids and infected
with SeV. The reporter assay was performed as described in Fig 7A. (B) The 293T cells con-
taining dox-inducible TEVP were transfected with the increasing amount of the V5-LSM14A--
TEVP-HA plasmid and the TEVP expression was induced using the indicated concentrations
of doxycycline. The LSM14A cleavage was monitored by western blot with anti-HA antibodies.
The small amount of cleavage product seen in the untreated cells is reflective of the leakiness
of the dox promoter.
(TIF)
S1 File. Proteins cleaved in CVB3-infected HeLa cells at 4h post-infection. The list of cleav-
age peptides and their corresponding proteins is shown. The proteins cleaved at 2Apro motifs
are highlighted in blue while those cleaved at 3Cpro motifs are highlighted in red. Further
details can be found in the “Read me” sheet of the excel file.
(XLS)
S2 File. The cleavage peptides and their corresponding proteins identified in HeLa cells
infected with CVB3, PV, HRV, EV70, and EV71. Instructions to read the data are provided
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in the “Read me” sheet of the excel file.
(XLSX)
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